Long-Term Complete Response to Pembrolizumab in Tumor Mutation Burden-High Small Cell Lung Cancer: A Case Report.

IF 0.7 Q4 ONCOLOGY

Case Reports in Oncology Pub Date : 2025-03-06 eCollection Date: 2025-01-01 DOI:10.1159/000544103

Kiyohide Komuta, Kei Kunimasa, Akito Miyazaki, Shun Futamura, Tsunehiro Tanaka, Takahisa Kawamura, Takako Inoue, Motohiro Tamiya, Kazumi Nishino

{"title":"Long-Term Complete Response to Pembrolizumab in Tumor Mutation Burden-High Small Cell Lung Cancer: A Case Report.","authors":"Kiyohide Komuta, Kei Kunimasa, Akito Miyazaki, Shun Futamura, Tsunehiro Tanaka, Takahisa Kawamura, Takako Inoue, Motohiro Tamiya, Kazumi Nishino","doi":"10.1159/000544103","DOIUrl":null,"url":null,"abstract":"Introduction: Extensive-stage small-cell lung cancer (ED-SCLC) has a poor prognosis. There are few case reports on the therapeutic effect of pembrolizumab in advanced SCLC with high tumor mutation burden (TMB-high).Case presentation: A 65-year-old woman was diagnosed with ED-SCLC. The initial treatment regimen included carboplatin, etoposide, and durvalumab. Following the administration of durvalumab, etoposide was discontinued due to an anaphylactic reaction immediately after its initiation. The patient was unable to continue the same regimen and was switched to cisplatin and irinotecan therapy. A FoundationOne panel test was submitted at the same time, and TMB-high was detected. After four courses of cisplatin and irinotecan therapy, pembrolizumab was introduced, and a complete response (CR) was maintained for 18 months.Conclusion: We report a rare case of a long-term response to pembrolizumab in ED-SCLC with TMB-high, highlighting the potential for targeted immunotherapy in such cases.","PeriodicalId":9625,"journal":{"name":"Case Reports in Oncology","volume":"18 1","pages":"443-448"},"PeriodicalIF":0.7000,"publicationDate":"2025-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11964409/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Case Reports in Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1159/000544103","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Extensive-stage small-cell lung cancer (ED-SCLC) has a poor prognosis. There are few case reports on the therapeutic effect of pembrolizumab in advanced SCLC with high tumor mutation burden (TMB-high).

Case presentation: A 65-year-old woman was diagnosed with ED-SCLC. The initial treatment regimen included carboplatin, etoposide, and durvalumab. Following the administration of durvalumab, etoposide was discontinued due to an anaphylactic reaction immediately after its initiation. The patient was unable to continue the same regimen and was switched to cisplatin and irinotecan therapy. A FoundationOne panel test was submitted at the same time, and TMB-high was detected. After four courses of cisplatin and irinotecan therapy, pembrolizumab was introduced, and a complete response (CR) was maintained for 18 months.

Conclusion: We report a rare case of a long-term response to pembrolizumab in ED-SCLC with TMB-high, highlighting the potential for targeted immunotherapy in such cases.

查看原文本刊更多论文

派姆单抗治疗肿瘤突变负担高的小细胞肺癌的长期完全缓解：1例报告。

广泛期小细胞肺癌（ED-SCLC）预后较差。关于派姆单抗在晚期SCLC高肿瘤突变负荷（TMB-high）治疗效果的病例报道很少。病例介绍：一名65岁女性被诊断为ED-SCLC。初始治疗方案包括卡铂、依托泊苷和杜伐单抗。在给予杜伐单抗后，依托泊苷因其开始后立即发生过敏反应而停药。患者无法继续相同的治疗方案，转而使用顺铂和伊立替康治疗。同时提交FoundationOne面板测试，检测到TMB-high。顺铂和伊立替康治疗4个疗程后，引入派姆单抗，完全缓解（CR）维持了18个月。结论：我们报告了一例罕见的pembrolizumab治疗ED-SCLC伴TMB-high的长期应答病例，强调了在此类病例中靶向免疫治疗的潜力。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊